Argenx Analyst Ratings
The Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Adopted Negative Opinion On Approval Of Eisai/Biogen's Lecanemab As Treatment For Early Alzheimer's Disease, Eisai Said It Will Seek Re-Examination Of The Opinion
Biogen-partnered Alzheimer's Therapy Fails to Clear EU Hurdle
Vertex Pharmaceuticals Analyst Ratings
Sage Therapeutics Cut to Neutral at J.P. Morgan on Pipeline Concerns
Market Whales and Their Recent Bets on AMGN Options
This Is What Whales Are Betting On Gilead Sciences
Actinium Wins FDA Nod to Conduct Clinical Trial for Radiotherapy
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Viking Sends Lilly, Novo Lower as Obesity Drug Enters Late-stage Program
Argenx SE Beats Top-line and Bottom-line Estimates; Updates FY24 Outlook
Icon Non-GAAP EPS of $3.75 Beats by $0.08, Revenue of $2.12B Misses by $20M
Jefferies Downgrades IQVIA to Hold, Cites Subdued Market Outlook
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
Argenx SE 1H Earnings Preview
Here's How Much You Would Have Made Owning Moderna Stock In The Last 5 Years
Notable Earnings Before Thursday's Open
Oppenheimer Upgrades Argenx to Outperform, Cites Vyvgart Hytrulo
Albemarle Is Out of Wells Fargo's Signature Picks
Here's How Much $100 Invested In Icon 15 Years Ago Would Be Worth Today